XERS News and Press, Xeris Pharmaceuticals Inc. From 03/25/19

Data from a Phase 2 study in congenital hyperinsulinism (CHI) shared at ENDO 2019 and a budget impact model presented at AMCP reinforce the utility of Xeris’ ready-to-use, liquid-stable glucagon Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leve...

Dosing is underway in a Phase 2 clinical trial evaluating Xeris Pharmaceuticals' (NASDAQ: XERS ) ready-to-use, room temperature-stable liquid glucagon in type 1 diabetics who experience exercise-induced hypoglycemia. More news on: Xeris Pharmaceuticals, Inc., Healthcare stocks news, ...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has now begun dosing patients in a Phase 2 trial with its rea...

Xeris Pharmaceuticals ( XERS ) is developing a resolution to a major dilemma in the diabetic population using their exclusive technologies for the delivery of ready-to-use, room temperature stable formulations. Although Xeris is a recent IPO , the company's researchers have been hard at w...

Xeris Pharmaceuticals (NASDAQ: XERS ): Q4 GAAP EPS of -$0.98 misses by $0.25 . More news on: Xeris Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, Read more ...

Continuing to execute commercial build and launch readiness for Gvoke HypoPen™ Advancing pipeline of preclinical and clinical development-stage products Cash position of $112.6 million at year-end 2018; February 2019 public offering raised additional $55.6 million to support...

Self-respect--the secure feeling that no one, as yet, is suspicious .” ― H.L. Mencken We start a new weekly feature today here at The Insiders Forum. Every week we will be providing very brief overviews of five interesting stocks insiders are currently buying. I have always ...

CHICAGO, March 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on February 27, 201...

CHICAGO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chair...

Motif Bio (NASDAQ: MTFB ) -75%  on receiving CRL from FDA. More news on: Motif Bio, Inovio Pharmaceuticals, Inc., Sierra Wireless, Inc., Stocks on the move, Read more ...